Bill..

Odd Year?

Choose ?..

Findings culled from a new method for aggregating and making sense of data in the FDA’s Adverse Event Reporting System (AERS) present a surprising glimpse at the postmarketing adverse event data for statins.

The study found a class-wide variation in muscle-related adverse event reports. The results linked rosuvastatin (Crestor, AstraZeneca) with the highest percentage risk in 6 categories, including myopathy (general), myalgia, myositis, rhabdomyolysis, joints and tendons, muscle atrophy and injury, and muscle coordination and weakness. Pravastatin (Pravachol, Bristol-Myers Squibb) and lovastatin (Mevacor, Merck) demonstrated the best muscle-related safety profile.

“The results were surprising because in the literature it’s generally regarded that Crestor is very safe ... and Crestor, across the board, seemed to be linked to more adverse events in the categories that we searched than the other statin drugs” said Keith Hoffman, PhD, vice president, Scientific Affairs, AdverseEvents, Inc.

Through RxFilter, the company identified more than 150,000 muscle-related adverse event reports in 6 categories linked to statins between January 1, 2004 and March 31, 2011. The drugs included atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), pravastatin (Pravachol), rosuvastatin (Crestor), fluvastatin (Lescol), as well as generic equivalents and foreign designations. Percent risk calculations were determined based on the number of primary suspect adverse events linked to each statin, divided by an estimated number of patients exposed to the drugs during the study period. A ranked risk measure was used to calculate within-drug comparisons.

The results indicated that Crestor had the highest percent risk in each of 6 adverse event categories examined, while Pravachol and Mevacor appeared to have the least.

The company’s database is now online at www.adverseevents.com. Formulary JournalClinical Pharmacology  November 04, 2011

Early...Huh?

Louder..

Hers..

Fall Back?

Next price..?

A series of social media posts from U.S. Sen. Bernie Sanders sent shares of Eli Lilly and Co. briefly tumbling to a seven-month low.
Sanders' Twitter account posted a link to a Washington Post article detailing the decades-long price increase of a Lilly insulin called Humalog. The price of Humalog has risen from $21 a vial to more than $250 during the last 20 years, according to the Post.

The tweets went out to Sanders' 2.7 million Twitter followers. They were not signed by Sanders.  Sanders' account posted several more messages that were sharply critical of the Indianapolis drugmaker.

Lilly in a statement defended its pricing of Humalog, noting the product's revenue has been lagging.
Sanders also targeted Lilly competitor Novo Nordisk, a Danish drugmaker whose insulin price has risen at a rate similar to Humalog, according to the Post.

What is next then?

BARF..

Disgusted..